uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, T2 Karolinska Univ Hosp, Stockholm, Sweden.; Eskilstuna Cty Hosp, Dept Surg, Eskilstuna, Sweden..
Karolinska Inst, Dept Mol Med & Surg, Upper Gastrointestinal Res, Stockholm, Sweden..
Karolinska Inst, Dept Mol Med & Surg, Upper Gastrointestinal Res, Stockholm, Sweden..
2017 (English)In: United European Gastroenterology journal, ISSN 2050-6406, E-ISSN 2050-6414, Vol. 5, no 8, p. 1123-1128Article in journal (Refereed) Published
Abstract [en]

Background The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design. Methods This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression. Results There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23% reduced risk (OR 0.77; 95% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR) 0.65; 95% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60% (IRR 0.40; 95% CI: 0.18-0.88) in women who used MHT3 years compared to women with <1 year of MHT use. The type of MHT did not change the results. Conclusion Systemic MHT use might reduce the risk of pancreatic cancer.

Place, publisher, year, edition, pages
SAGE PUBLICATIONS INC , 2017. Vol. 5, no 8, p. 1123-1128
Keywords [en]
Menopausal hormone therapy, pancreatic cancer, etiology, epidemiology, population-based study
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-343571DOI: 10.1177/2050640617702060ISI: 000416825100008OAI: oai:DiVA.org:uu-343571DiVA, id: diva2:1187011
Available from: 2018-03-02 Created: 2018-03-02 Last updated: 2018-03-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text
By organisation
Centrum för klinisk forskning i Sörmland (CKFD)
In the same journal
United European Gastroenterology journal
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf